GSK Acquires Aiolos Bio in $1.4 Billion Deal

Acquisition brings potential breakthrough asthma treatment AIO-001 into GSK's portfolio.

GSK has acquired US company Aiolos Bio in a $1.4 billion deal, gaining access to a potentially revolutionary asthma treatment, AIO-001.
AIO-001, still in medical trials, is an antibody that can be used to treat adult patients with severe asthma and is expected to reduce the need for inhalers.
The treatment, which is administered twice a year, could cater to 40% of severe asthma sufferers who are not adequately treated by GSK's current drugs.
Aiolos Bio was only founded in 2023 but has already raised $245 million from venture capital investors.
GSK will also pay tiered royalties to Jiangsu Hengrui Pharmaceuticals, the Chinese firm that licensed AIO-001 to Aiolos for use outside of China.